ZALTRAP
Drug
GENZYME CORPORATION
Total Payments
$1.5M
Transactions
568
Doctors
462
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $5,660 | 4 | 4 |
| 2020 | $60,380 | 7 | 2 |
| 2019 | $306,555 | 41 | 3 |
| 2018 | $476,849 | 59 | 44 |
| 2017 | $660,520 | 457 | 412 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 89 | 87.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $131,400 | 2 | 8.7% |
| Education | $37,789 | 450 | 2.5% |
| Consulting Fee | $14,786 | 5 | 1.0% |
| Travel and Lodging | $8,247 | 4 | 0.5% |
| Food and Beverage | $460.35 | 18 | 0.0% |
Payments by Type
Research
$1.3M
89 transactions
General
$192,682
479 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II Study of VEGF-Trap plus Modified FOLFOX 6 in Previously Untreated Patients with Metastatic Colorectal Cancer | GENZYME CORPORATION | $498,879 | 0 |
| Phase I/II Study of Capecitabine plus Aflibercept in Metastatic Colorectal Cancer | GENZYME CORPORATION | $275,019 | 0 |
| Phase II Study of Aflibercept in Patients with Advanced, Progressive Carcinoid Tumors | SANOFI US SERVICES INC. | $248,090 | 1 |
| Randomized Phase II Study of FOLFOX +/- Aflibercept in metastatic esophagogastric cancer | GENZYME CORPORATION | $144,624 | 0 |
| Phase II Study of Aflibercept in Patients with Advanced, Progressive Carcinoid Tumors | GENZYME CORPORATION | $70,933 | 0 |
| Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP? administered in combination with FOLFIRI for the treatment of patients with met | SANOFI US SERVICES INC. | $40,775 | 0 |
| Interest of CT Morphological Evaluation in Patients with Metastatic Colorectal Cancer Treated with ZIV-Aflibercept | GENZYME CORPORATION | $26,268 | 0 |
| Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) in current clinical practice: OZONE | SANOFI-AVENTIS U.S. LLC | $9,261 | 2 |
| Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP administered in combination with FOLFIRI for the treatment of patients with meta | SANOFI US SERVICES INC. | $1,000 | 0 |
| Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP? administered in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer in current clinical practice: | SANOFI US SERVICES INC. | $1,000 | 0 |
| Safety and effectiveness of aflibercept FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) in current clinical practice: OZONE | SANOFI-AVENTIS U.S. LLC | $990.66 | 2 |
| Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the United States | SANOFI-AVENTIS U.S. LLC | $441.85 | 1 |
Top Doctors Receiving Payments for ZALTRAP — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Winchester, VA | $99.95 | 1 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $99.95 | 1 |
| , M.D | Specialist | Lansdowne, VA | $99.95 | 1 |
| , MD | Hematology & Oncology | Bethesda, MD | $99.95 | 1 |
| , M.D | Hematology & Oncology | Elk Grove Village, IL | $99.95 | 1 |
| , M.D | Hematology & Oncology | Phoenix, AZ | $99.95 | 1 |
| , M.D | Ophthalmology | Seattle, WA | $99.95 | 1 |
| , MD | Hematology & Oncology | Wayne, NJ | $99.95 | 1 |
| , M.D | Hematology & Oncology | Manasquan, NJ | $99.95 | 1 |
| , MD | Hematology & Oncology | Kokomo, IN | $99.95 | 1 |
| , M.D | Hematology & Oncology | Baltimore, MD | $99.95 | 1 |
| , D.O | Internal Medicine | Oak Brook, IL | $99.95 | 1 |
| , D.O | Hematology & Oncology | Lubbock, TX | $99.95 | 1 |
| , M.D | Hematology & Oncology | Buffalo, NY | $99.95 | 1 |
| , M.D | Hematology & Oncology | Phoenix, AZ | $99.95 | 1 |
| , MD | Hematology & Oncology | Buffalo, NY | $99.95 | 1 |
| , MD | Hematology & Oncology | Las Vegas, NV | $99.95 | 1 |
| , MD | Medical Oncology | Chesapeake, VA | $99.95 | 1 |
| , D.O | Hematology & Oncology | Brooklyn, NY | $99.95 | 1 |
| , MD | Internal Medicine | Brooklyn, NY | $99.95 | 1 |
| , DO | Hematology & Oncology | Frankfort, IL | $99.95 | 1 |
| , M.D | Medical Oncology | Indianapolis, IN | $99.95 | 1 |
| , M.D | Hematology & Oncology | Elk Grove Village, IL | $99.95 | 1 |
| , MD | Medical Oncology | Bend, OR | $99.95 | 1 |
| , MD FACP | Medical Oncology | Woodbridge, VA | $99.95 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $1.0M
- SANOFI US SERVICES INC. $415,865
- SANOFI-AVENTIS U.S. LLC $60,810
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 462
- Transactions 568
About ZALTRAP
ZALTRAP is a drug associated with $1.5M in payments to 462 healthcare providers, recorded across 568 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2023. In 2023, $5,660 was paid across 4 transactions to 4 doctors.
The most common payment nature for ZALTRAP is "Unspecified" ($1.3M, 87.2% of total).
ZALTRAP is associated with 12 research studies, including "A Phase II Study of VEGF-Trap plus Modified FOLFOX 6 in Previously Untreated Patients with Metastatic Colorectal Cancer" ($498,879).